Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBioatla Inc

Bioatla Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.0 USD -0.09 ( 4.31%)
Last update at 2026-11-06T19:26:00Z
VOLUME
727
Market Cap
2.30M

Momentum Score

…

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.55
Low
2.09
High
52 Week Price Range
1.07
Low
71.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioAtla is a clinical-stage biopharmaceutical firm developing conditionally active biologics that preferentially activate in the tumor microenvironment to improve therapeutic index. Long-term growth drivers include clinical progress, platform licensing or collaborations and expansion across oncology indications, which may benefit from demand for safer targeted therapies and enable multiple antibody programs.
Key risks are clinical and regulatory uncertainty for experimental therapies, ongoing operating losses with likely future financing that could dilute shareholders, and strong competition in oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.09
Dividend Yield
-
Revenue TTM
8.50M
Revenue Per Share
6.14
Gross Profit TTM
-16.06M
Debt / Equity
-0.17
ROE
-813.88%
Net Debt
-0.92M
ROCE
732.70%
Diluted EPS TTM
-23.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.61M -69.78M -123.46M -106.48M -95.40M
Minority interest - - - - 0.00M
Net income -59.61M -69.78M -123.46M -105.28M -95.41M
Selling general administrative 17.73M 21.85M 25.96M 28.79M 38.42M
Selling and marketing expenses - - 1.22M - -
Gross profit 2.00M 10.07M -1.22M - 0.25M
Reconciled depreciation 0.37M 0.93M 1.15M 1.20M 1.33M
Ebit -59.30M -73.94M -123.46M -108.14M -96.44M
Ebitda -58.93M -73.02M -122.24M -106.48M -94.76M
Depreciation and amortization 0.37M 0.93M 1.22M 1.66M 1.68M
Non operating income net other - - - 1.66M -
Operating income -59.30M -73.94M -129.69M -108.14M -96.44M
Other operating expenses 61.30M 84.94M 129.69M 108.14M 96.69M
Interest expense - - - -1.66M 0.00M
Interest income 0.84M 3.37M 5.72M 1.65M 0.35M
Net interest income 0.84M 3.37M 5.72M 1.65M 0.35M
Income tax expense - - - -1.20M 0.00M
Total revenue 2.00M 11.00M 0.00M 0.00M 0.25M
Total operating expenses 61.30M 84.02M 128.47M 108.14M 96.69M
Cost of revenue - 0.93M 1.22M - -
Total other income expense net -0.30M 4.17M 6.22M 1.66M 1.04M
Net income from continuing ops -59.61M -69.78M -124.08M -106.48M -95.40M
Net income applicable to common shares - - - -106.48M -95.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13.83M 52.42M 119.66M 225.74M 254.42M
Other current assets 0.90M 2.19M 4.93M 0.54M 0.50M
Total liab 50.02M 38.16M 48.99M 45.40M 43.60M
Total stockholder equity -36.19M 14.27M 70.67M 180.34M 210.82M
Other current liab 12.30M 11.80M 22.90M 17.38M 17.25M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -545.65M -486.04M -416.26M -292.80M -186.32M
Other liab - - - 19.81M 19.81M
Other assets - - 0.00M 0.15M 0.15M
Cash 7.12M 49.05M 111.47M 215.51M 244.98M
Total current liabilities 21.92M 14.54M 28.34M 23.13M 19.81M
Net debt -0.92M -48.21M -109.01M -211.53M -239.61M
Short term debt 1.43M 0.84M 1.62M 1.52M 1.39M
Short long term debt total 6.20M 0.84M 2.46M 3.98M 5.37M
Other stockholder equity 509.45M 500.30M 486.93M 473.13M 397.14M
Property plant equipment - - - 2.73M 6.98M
Total current assets 8.01M 51.23M 116.41M 220.43M 247.29M
Net tangible assets - - - 180.34M 210.82M
Accounts payable 8.19M 1.90M 3.82M 4.23M 1.18M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -292.80M -186.32M
Non currrent assets other 0.16M - 0.15M 0.15M 0.15M
Non current assets total 5.82M 1.19M 3.25M 5.30M 7.13M
Capital lease obligations 6.20M 0.84M 2.46M 3.98M 5.37M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.12M -0.27M -0.92M
Change to liabilities - - - 3.41M 7.99M
Total cashflows from investing activities - - -0.10M -0.27M -0.92M
Net borrowings 7.12M 0.00M - - -
Total cash from financing activities 6.28M 9.51M 0.08M 61.21M 69.51M
Change to operating activities - - - -3.12M -0.57M
Net income -59.61M -69.78M -123.46M -106.48M -95.40M
Change in cash -41.93M -62.42M -104.04M -29.47M 6.37M
Begin period cash flow 49.05M 111.47M 215.51M 244.98M 238.60M
End period cash flow 7.12M 49.05M 111.47M 215.51M 244.98M
Total cash from operating activities -48.20M -71.94M -104.02M -90.42M -62.21M
Issuance of capital stock 0.00M 9.21M 0.00M 61.68M 70.99M
Depreciation 0.37M 0.93M 1.22M 1.20M 1.33M
Other cashflows from investing activities - - - 0.00M -
Sale purchase of stock 0.10M 0.34M -0.00M 0.29M 0.29M
Other cashflows from financing activities -0.95M 0.30M -0.26M -0.76M -1.48M
Change to netincome - - - 14.58M 24.43M
Capital expenditures 0.00M 0.00M 0.10M 0.27M 0.92M
Change receivables - - - - 0.00M
Cash flows other operating - - - -3.12M -0.57M
Cash and cash equivalents changes - - - -29.47M 6.37M
Change in working capital 4.28M -11.20M 4.68M 0.29M 7.42M
Stock based compensation 5.43M 8.92M 13.54M 14.56M 25.12M
Other non cash items 1.32M -0.81M 0.00M 0.01M 0.00M
Free cash flow -48.20M -71.94M -104.11M -90.69M -63.14M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BCAB
Bioatla Inc		 -0.09
4.31%		 2.00 - - 0.27 2.68 0.80 0.31
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Bioatla Inc

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

11085 Torreyana Road, San Diego, CA, United States, 92121

858 558 0708

https://www.bioatla.com

41

Name Title Year Born
Dr. Jay M. Short Ph.D. Co-Founder, CEO & Chairman 1958
Mr. Scott Andrew Smith Pres & Director 1962
Mr. Richard A. Waldron Chief Financial Officer 1954
Dr. Eric L. Sievers M.D. Chief Medical Officer 1964
Mr. Christian Vasquez VP of Fin., Corp. Controller & Sec. 1975
Mr. Philippe Martin Chief Clinical Devel. & Operations 1976
Lisa M. Pelton Accounting Mang. NA
Ms. Susie Melody Sr. VP of HR NA
Dr. Cathy Chang Ph.D. Sr. VP of R&D NA
Ms. Monica Sullivan Sr. VP of Intellectual Property & Contracts NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…